The wider scope of Scenesse:
For newcomers it might be interesting to know what the future might bring once Scenesse is successfully marketed for EPP, which is about to happen as I write this.
I don't have time to look up all the links to substantiate the following, but you can look it all up - it's there.
1) Scenesse is highly effective in HHD and has completed a physician led phase IIa in Italy. I expect label extension for this condition.
2) The FDA is sympathetic to the EPP sufferers and the APF is pushing hard to get the drug approved in the US ASAP. I believe it will happen either this summer or the next.
3) Scenesse has been trialed in numerous conditions, and I think we will see label extensions or off label (in the US) for these conditions: SCC, Rosscea, OTC, PMLE et al.
4) Scenesse has proven accelerate repigmentation in Vitiligo and this is backed by the Worlds most renowned scientists and numerous trials. A US phase III will put Scenesse on the brink of becoming standard care for millions of sufferers.
5) Scenesse (a-msh) activates p53, holds DNA restoring properties and is a potent antiinflamatory agent. These properties are not even fully explored by the company as of yet.
6) Scenesse cleared up acne and psoreasis completely in small trials.
7) Clinuvel holds numerous interesting patents for other uses of afamelanotide. E.g. as a general UV protectant for redheads who are much more at risk for developing skin cancer.
8) Scenesse is developing CUV9900 and VLX001 - two topical a-msh agents that can be used as a pediatric version of Scenesse, a self administered follow up treatment for Vitiligo, a general protectant for skin cancer and the application that we do not speak of. Begins with C and ends with osmetic.
9) If you go to google groups and read some of the amazing research Uho has made throughout the years you will see that this is only the beginning. Scenesse is a wonder drug with many applications. EPP is only the beginning.
